T. Rowe Price Associates’s Insulet PODD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$59.3M Buy
282,637
+6,757
+2% +$1.7M 0.01% 729
2025
Q4
$78.4M Buy
275,880
+40,284
+17% +$12.6M 0.01% 685
2025
Q3
$72.7M Buy
235,596
+11,538
+5% +$3.61M 0.01% 691
2025
Q2
$70.4M Buy
224,058
+17,801
+9% +$5.14M 0.01% 646
2025
Q1
$54.2M Buy
206,257
+3,529
+2% +$955K 0.01% 704
2024
Q4
$52.9M Buy
202,728
+744
+0.4% +$187K 0.01% 736
2024
Q3
$47M Sell
201,984
-205,677
-50% -$42.2M 0.01% 771
2024
Q2
$82.3M Sell
407,661
-28,263
-6% -$5.09M 0.01% 587
2024
Q1
$74.7M Sell
435,924
-119,193
-21% -$22.2M 0.01% 613
2023
Q4
$120M Sell
555,117
-479,319
-46% -$82.2M 0.02% 509
2023
Q3
$165M Sell
1,034,436
-50,970
-5% -$11.4M 0.02% 428
2023
Q2
$313M Sell
1,085,406
-1,173,258
-52% -$356M 0.04% 317
2023
Q1
$720M Sell
2,258,664
-833,095
-27% -$247M 0.11% 194
2022
Q4
$910M Sell
3,091,759
-173,046
-5% -$47.7M 0.15% 147
2022
Q3
$749M Sell
3,264,805
-203,015
-6% -$50.8M 0.12% 165
2022
Q2
$756M Sell
3,467,820
-24,892
-0.7% -$5.66M 0.1% 220
2022
Q1
$930M Buy
3,492,712
+3,088,175
+763% +$758M 0.09% 220
2021
Q4
$108M Sell
404,537
-6,474
-2% -$1.88M 0.01% 741
2021
Q3
$117M Sell
411,011
-3,676
-0.9% -$1.05M 0.01% 716
2021
Q2
$114M Sell
414,687
-23,159
-5% -$6.3M 0.01% 738
2021
Q1
$114M Sell
437,846
-8,024
-2% -$2.15M 0.01% 730
2020
Q4
$114M Sell
445,870
-5,329
-1% -$1.32M 0.01% 688
2020
Q3
$107M Sell
451,199
-111,610
-20% -$23.5M 0.01% 637
2020
Q2
$109M Sell
562,809
-86,887
-13% -$16.6M 0.01% 616
2020
Q1
$108M Sell
649,696
-23,069
-3% -$4.22M 0.02% 554
2019
Q4
$115M Sell
672,765
-116,157
-15% -$19.4M 0.01% 622
2019
Q3
$130M Buy
788,922
+290,326
+58% +$40.8M 0.02% 542
2019
Q2
$59.5M Buy
498,596
+44,227
+10% +$4.53M 0.01% 817
2019
Q1
$43.2M Buy
454,369
+138,758
+44% +$11.9M 0.01% 926
2018
Q4
$25M Sell
315,611
-50,583
-14% -$4.28M ﹤0.01% 1074
2018
Q3
$38.8M Sell
366,194
-18,432
-5% -$1.73M 0.01% 1008
2018
Q2
$33M Buy
384,626
+148,519
+63% +$13.3M 0.01% 1035
2018
Q1
$20.5M Buy
236,107
+206,613
+701% +$16M ﹤0.01% 1176
2017
Q4
$2.04M Sell
29,494
-1,410
-5% -$92.5K ﹤0.01% 1579
2017
Q3
$1.7M Hold
30,904
﹤0.01% 1614
2017
Q2
$1.59M Buy
30,904
+2
+0% +$87 ﹤0.01% 1617
2017
Q1
$1.33M Hold
30,902
﹤0.01% 1697
2016
Q4
$1.16M Sell
30,902
-156,520
-84% -$5.83M ﹤0.01% 1725
2016
Q3
$7.67M Sell
187,422
-2,569
-1% -$102K ﹤0.01% 1362
2016
Q2
$5.75M Sell
189,991
-1,830
-1% -$56.9K ﹤0.01% 1381
2016
Q1
$6.36M Sell
191,821
-188,540
-50% -$5.92M ﹤0.01% 1352
2015
Q4
$14.4M Buy
380,361
+12,350
+3% +$416K ﹤0.01% 1189
2015
Q3
$9.54M Buy
368,011
+5,770
+2% +$175K ﹤0.01% 1315
2015
Q2
$11.2M Buy
362,241
+8,700
+2% +$256K ﹤0.01% 1320
2015
Q1
$11.8M Buy
353,541
+165,660
+88% +$5.59M ﹤0.01% 1293
2014
Q4
$8.65M Buy
187,881
+167,760
+834% +$7.18M ﹤0.01% 1359
2014
Q3
$741K Sell
20,121
-218,855
-92% -$7.99M ﹤0.01% 1810
2014
Q2
$9.48M Sell
238,976
-731,953
-75% -$28.1M ﹤0.01% 1332
2014
Q1
$46M Sell
970,929
-128,117
-12% -$5.67M 0.01% 884
2013
Q4
$40.8M Buy
1,099,046
+570,300
+108% +$21.1M 0.01% 901
2013
Q3
$19.2M Sell
528,746
-259,954
-33% -$8.72M ﹤0.01% 1091
2013
Q2
$24.8M Buy
+788,700
New +$22.3M 0.01% 1014

Other funds holding PODD

T. Rowe Price Associates's PODD Position: Q1 2026 in Review

T. Rowe Price Associates increased its Insulet (PODD) stake by 2.4% in Q1 2026, buying an estimated $1.7M and bringing the position to 282,637 shares worth $59.3M. The position accounts for 0.01% of the portfolio, ranked #729.

T. Rowe Price Associates first reported a position in PODD in Q2 2013 and has held it in 52 quarters since. The position peaked at $930M in Q1 2022. 784 funds tracked by Wall St. Rank hold PODD as of Q1 2026.

  • T. Rowe Price Associates held 282,637 shares of Insulet worth $59.3M as of Q1 2026.
  • T. Rowe Price Associates bought 6,757 Insulet shares in Q1 2026, an estimated $1.7M.
  • Insulet made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #729 holding.
  • T. Rowe Price Associates first reported a position in Insulet in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Insulet position peaked at $930M in Q1 2022.
  • 784 funds tracked by Wall St. Rank held Insulet as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.